We thank the responding authors for their comments on our study, 1 which deal primarily with trial design. The timing of postcontrast creatinine sampling is a limitation of all trials on this topic. The CARE trial is unique because it is the first trial in which the exact timing of the postcontrast samples was reported and because 83% of the single postcontrast samples were collected during a time period when most cases of contrast-enhanced nephropathy (CIN) are known to occur (ie, 2 to 3 days after contrast administration). Few patients had samples taken beyond 71 hours, and it is very likely that the critical increases in serum creatinine observed at day 4 or 5 were already present at day 2 or 3 after contrast. We do not believe that any bias was introduced by measurements at these later time points or that the rates observed for these small numbers of patients are meaningful.
